Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma

Por Wang, Ling, Lam, Hung, Shou, Yaping, Galaznik, Aaron
Publicado no Oncotarget (2019)

A der(8)t(8;11) chromosome in the Karpas-620 myeloma cell line expresses only Cyclin D1: Yet both Cyclin D1 and MYC are repositioned in close proximity to the 3′ IGH enhancer

Por Dib, Amel, Glebov, Oleg K., Shou, Yaping, Singer, Robert H., Kuehl, W. Michael
Publicado em 2008

Predicting Outcomes in Patients With Diffuse Large B-Cell Lymphoma Treated With Standard of Care

Por Galaznik, Aaron, Reich, Christian, Klebanov, Greg, Khoma, Yuriy, Allakhverdiiev, Eldar, Hather, Greg, Shou, Yaping
Publicado no Cancer Inform (2019)

Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma

Por Galaznik, Aaron, Huelin, Rachel, Stokes, Michael, Guo, Yelan, Hoog, Meredith, Bhagnani, Tarun, Bell, Jill, Shou, Yaping
Publicado no Future Sci OA (2018)

Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma

Por Shou, Yaping, Martelli, Maria L., Gabrea, Ana, Qi, Ying, Brents, Leslie A., Roschke, Anna, Dewald, Gordon, Kirsch, Ilan R., Bergsagel, P. Leif, Kuehl, W. Michael
Publicado em 2000

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Por Kumar, Shaji K., Bensinger, William I., Zimmerman, Todd M., Reeder, Craig B., Berenson, James R., Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj, Di Bacco, Alessandra, Yu, Jiang, Shou, Yaping, Niesvizky, Ruben
Publicado no Blood (2014)

Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome–Pos...

Por Branford, Susan, Kim, Dong-Wook, Soverini, Simona, Haque, Ariful, Shou, Yaping, Woodman, Richard C., Kantarjian, Hagop M., Martinelli, Giovanni, Radich, Jerald P., Saglio, Giuseppe, Hochhaus, Andreas, Hughes, Timothy P., Müller, Martin C.
Publicado no J Clin Oncol (2012)

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Por Hochhaus, Andreas, Saglio, Giuseppe, Larson, Richard A., Kim, Dong-Wook, Etienne, Gabriel, Rosti, Gianantonio, De Souza, Carmino, Kurokawa, Mineo, Kalaycio, Matt E., Hoenekopp, Albert, Fan, Xiaolin, Shou, Yaping, Kantarjian, Hagop M., Hughes, Timothy P.
Publicado no Blood (2013)

The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells

Por Oehler, Vivian G., Guthrie, Katherine A., Cummings, Carrie L., Sabo, Kathleen, Wood, Brent L., Gooley, Ted, Yang, Taimei, Epping, Mirjam T., Shou, Yaping, Pogosova-Agadjanyan, Era, Ladne, Paula, Stirewalt, Derek L., Abkowitz, Janis L., Radich, Jerald P.
Publicado em 2009

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Por Hughes, Timothy, Saglio, Giuseppe, Branford, Susan, Soverini, Simona, Kim, Dong-Wook, Müller, Martin C., Martinelli, Giovanni, Cortes, Jorge, Beppu, Lan, Gottardi, Enrico, Kim, Dongho, Erben, Philipp, Shou, Yaping, Haque, Ariful, Gallagher, Neil, Radich, Jerald, Hochhaus, Andreas
Publicado no J Clin Oncol (2009)

Targeting CD47 in Sézary syndrome with SIRPαFc

Por Johnson, Lisa D. S., Banerjee, Swati, Kruglov, Oleg, Viller, Natasja Nielsen, Horwitz, Steven M., Lesokhin, Alexander, Zain, Jasmine, Querfeld, Christiane, Chen, Robert, Okada, Craig, Sawas, Ahmed, O’Connor, Owen A., Sievers, Eric L., Shou, Yaping, Uger, Robert A., Wong, Mark, Akilov, Oleg E.
Publicado no Blood Adv (2019)

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Por Juric, Dejan, de Bono, Johann S., LoRusso, Patricia M., Nemunaitis, John, Heath, Elisabeth I., Kwak, Eunice L., Mercadé, Teresa Macarulla, Geuna, Elena, Jose de Miguel-Luken, Maria, Patel, Chirag, Kuida, Keisuke, Sankoh, Serap, Westin, Eric H., Zohren, Fabian, Shou, Yaping, Tabernero, Josep
Publicado no Clin Cancer Res (2017)

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Por Giles, Francis J., Abruzzese, Elisabetta, Rosti, Gianantonio, Kim, Dong-Wook, Bhatia, Ravi, Bosly, Andre, Goldberg, Stuart, Kam, Grace L.S., Jagasia, Madan, Mendrek, Wlodzimierz, Fischer, Thomas, Facon, Thierry, Dünzinger, Ulrich, Marin, David, Shou, Yaping, Gallagher, Neil J., Larson, Richard A., Mahon, Francois-Xavier, Baccarani, Michele, Cortes, Jorge, Kantarjian, Hagop M.
Publicado em 2010

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Por Kantarjian, Hagop M., Giles, Francis J., Bhalla, Kapil N., Pinilla-Ibarz, Javier, Larson, Richard A., Gattermann, Norbert, Ottmann, Oliver G., Hochhaus, Andreas, Radich, Jerald P., Saglio, Giuseppe, Hughes, Timothy P., Martinelli, Giovanni, Kim, Dong-Wook, Shou, Yaping, Gallagher, Neil J., Blakesley, Rick, Baccarani, Michele, Cortes, Jorge, le Coutre, Philipp D.
Publicado no Blood (2011)